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Anonymized data regarding patients diagnosed with ABC receiving bevacizumab during the period of 2012 to 2016 were retrieved from Auditron®, the proprietary Evidências-Kantar Health database of claims. Auditron® has information provided by over 50 health insurance companies (HIC) in the PHS, cover 4 million lives, which is the equivalent of 7% of those insured in the private market.
Chemotherapy regimens including bevacizumab for the treatment of ABC were identified and the direct cost of drugs was calculated using the SIMPRO official list of prices. Conversion rate was: 1U$ = R$ 3,3.
In parallel, a search on the published literature was performed to identify the scientific support for each of the requested regimens.
METHODS
Breast cancer (BC) is considered the most common type of cancer among women in the world and also in Brazil (excluding non-melanoma skin cancer), accounting for about 28% of new cases each year. It can also affect men, although it is rare, representing only 1% of the total cases of the disease. Relatively uncommon before age 35, the incidence of BC increases steadily afterwards, especially after age 50. Statistics indicate an increased incidence in both developed and developing countries. BC is the most frequently diagnosed neoplasm and considered to be the leading cause of cancer-related death among women (1) .
Since 1991, the mortality rate has been declining, suggesting the benefit of early detection, better diagnostic methods and more effective treatments. Nevertheless, these therapies have brought a considerable increase in the total cost of BC treatments (2) .
Issues related to the cost of cancer treatment have been the focus of discussions in many countries for quite some time. According to the American Society of Clinical Oncology (ASCO), high-quality treatment will be increasingly less accessible to large number of cancer patients unless steps are taken to reverse the current trends on therapy costs (3) .
Oncologic treatments represent a large portion of the expenses incurred in by the public and private health care systems in Brazil (4) . Alternatives have been sought in order to continue to deliver the treatments to the population in a sustainable fashion (5) .
The challenges are even bigger for BC treatments: the cost of medications is higher and since treatments are becoming longer, the final cost is consequently escalating.
Scientific publications have failed to demonstrate that bevacizumab has a positive impact in overall survival or quality of life in patients with advanced breast cancer (ABC).
Our goal was to assess through real world data (RWD) if oncologists continue to prescribe the medication for ABC despite the lack of evidence and how much do these regimens cost for health care providers in the Private Health Care System (PHS) in Brazil.
BACKGROUND
Most regimens with bevacizumab for ABC are prescribed based on studies that use progression-free survival as the main endpoint.
Almost 1 in five (17.2%) of all requests including bevacizumab for the treatment of ABC lack robust scientific evidence to support them. Some, are even prescribed based on extrapolations from studies on non-metastatic breast cancer.
Nevertheless, oncologists from all Brazilian regions still prescribe the drug in combination with other chemotherapy medications, generating a negative economic impact of the order of R$12, 830,330.28 (U$ 3,867,978.87) We retrieved 133 prescriptions including bevacizumab for patients with ABC from all regions of the country. Table 1 details the characteristics of the patients.
Bevacizumab was added to nine chemotherapy regimens: paclitaxel (110 requests); capecitabine (N=8); docetaxel (N=4); paclitaxel + carboplatin (N=4); gemcitabine (N=2); cisplatin + gemcitabine (N=2), navelbine (N=1) and paclitaxel + trastuzumab (N=1). Also, bevacizumab was requested as monotherapy for one patient (Table 2) . 
RESULTS
Chemotherapy regimens
